Bardia Moayedi is a partner in the firm’s corporate and securities group, with a primary emphasis on advising emerging growth and public companies throughout their life cycles, particularly in the life sciences, high-technology, financial technology, food and beverage, and clean-technology industries.
Bardia has significant experience representing companies and financial firms in a broad range of general corporate governance and transactional matters, including venture capital financings, mergers and acquisitions, debt offerings, spin-offs/divestitures, joint ventures, IPOs, follow-on offerings, and tender offers. He is a trusted advisor, often serving as the go-to outside counsel or lead counsel to his clients.
In addition to his normal areas of practice, Bardia is a member of the firm’s Coronavirus (COVID-19) Response Team, an interdisciplinary team of lawyers, formed quickly after recognizing the complex legal issues that businesses would confront as a result of the coronavirus. This group has issued legal alerts and newsletters on the topic and has hosted multiple webinars to address a range of concerns. The group remains committed to monitoring the issues and bringing as much clarity and guidance to clients as possible. More information is available in the COVID-19 Resource Center.
Prior to attending law school, Bardia worked at a prominent investment bank, where he focused on hedge funds and private equity funds. As an undergraduate, he played ice and roller hockey at UCLA.
Startups and Venture Capital
Extensive experience representing companies and venture capital firms in numerous convertible note, SAFE and seed financings
Extensive experience representing companies and venture capital firms in numerous Series A through pre-IPO preferred stock financings
Mergers and Acquisitions
Represented a therapeutics company in its over $600 million acquisition by a Fortune 100 company
Represented a medical device company in its $400 million acquisition by a Fortune 100 company
Represented a biotherapeutics company in its $300 million acquisition by a Fortune 100 company
Represented a high-technology company in its over $250 million acquisition by a Fortune 100 company
Represented a pharmaceutical company in its over $200 million acquisition by a publicly traded company
Represented a high-technology company in its $200 million acquisition by a publicly traded company
Represented a clinical-stage immunotherapy company in its over $200 million IPO
Represented a high-technology company it its over $100 million IPO
Represented a medical device company in its over $70 million IPO
Represented a biotherapeutics company in its over $50 million IPO
Represented a clinical-stage biosimilars company in its $50 million IPO
Represented a publicly traded company in its over $200 million tender offer
Represented a publicly traded company in its $200 million tender offer
University of San Diego School of Law, J.D.
University of California, Los Angeles, B.A.
UC Irvine Applied Innovation Incubator, Advisor
SDSU ZIP Launchpad, Advisor
UC Hastings Start-up Legal Garage, Advisor
San Diego Venture Group, Member
Business Forum International, Member
“IP for Startups - IP and Venture Fundraising,” Panelist, SBDC @ University of California, Irvine Beall Applied Innovation Incubator (January 27, 2021)
“Financial Recovery,” Panelist, SBDC @ University of California, Irvine Beall Applied Innovation Incubator, (August 18, 2020)